miR-126 Inhibitor miRisten

Phase 1Small molecule

miR-126 Inhibitor miRisten is one of 4 small molecule programs targeting Recurrent Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Acute Myeloid LeukemiaRecruiting

Recurrent Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Recurrent Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 1

2 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

2 3

Flotetuzumab

Bristol-Myers Squibb

Phase 1

1 4

miR-126 Inhibitor miRisten

CCity of Hope Medical Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Recurrent Acute Myeloid Leukemia

NCT07025564

Clinical

Trials by Indication[1]

Recurrent Acute Myeloid Leukemia1 trial

A Phase 1 Trial of miRisten in Adult Patients With Relapsed/Refractory AML

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07025564·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for miR-126 Inhibitor miRisten. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — miR-126 Inhibitor miRisten compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for miR-126 Inhibitor miRisten. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

miR-126 Inhibitor miRisten

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Recurrent Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News